18 March 2019 - Biogen’s Spinraza (nusinersen), a treatment for spinal muscular atrophy, is likely to obtain reimbursement as early as next month.
The pharmaceutical company and the National Health Insurance Service (NHIS) on Friday reached an agreement on pricing for the treatment of the rare neuromuscular disease. The negotiation talks for Spinraza pricing has been stuck until Thursday.
The Ministry of Health and Welfare’s health insurance policy review committee is to make the final decision on reimbursement for the drug. The pharmaceutical industry expects the committee may discuss it at the upcoming meeting in late March. If the scenario unfolds as predicted, Spinraza may get insurance benefit from April at the earliest.